Advocacy intelligence hub — real-time data for patient organizations
Novartis Pharmaceuticals — PHASE2
Assiut University
M.D. Anderson Cancer Center — PHASE2
Novartis Pharmaceuticals
Theradex — PHASE2
Qian Jiang
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance8
Busulfan
Otsuka Pharmaceutical
BOSULIF
Pfizer
Synribo
IVAX International GmbH
Nilotinib
Novartis
SCEMBLIX
Novartis
Roferon A
Hoffmann-La Roche, Inc.
DANZITEN
Azurity
Iclusig
Takeda
Danziten
(nilotinib)Orphan drugAzurity Pharmaceuticals, Inc.
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Nilotinib is an inhibitor of the BCR-ABL kinase. Nilotinib binds to and stabilizes the inactive conformation of the kinase do...
Bosulif
(bosutinib)Orphan drugPF PRISM C.V.
12.1 Mechanism of Action Bosutinib is a TKI. Bosutinib inhibits the BCR-ABL kinase that promotes CML; it is also an inhibitor of Src-family kinases in...
Scemblix
(asciminib)Orphan drugNovartis Pharmaceuticals Corporation
12.1 Mechanism of Action Asciminib is an ABL/BCR-ABL1 tyrosine kinase inhibitor. Asciminib inhibits the ABL1 kinase activity of the BCR::ABL1 fusion p...
Synribo
(omacetaxine mepesuccinate)Orphan drugIVAX International GmbH
Roferon A
(Interferon alfa-2a)Orphan drugHoffmann-La Roche, Inc.
Busulfex
(Busulfan)Orphan drugstandardOtsuka Pharmaceutical Company, Ltd
Alkylating Drug [EPC]
12.1 Mechanism of Action Busulfan is a bifunctional alkylating agent in which two labile methanesulfonate groups are attached to opposite ends of a fo...
Iclusig
(ponatinib)Orphan drugstandardTakeda Pharmaceuticals U.S.A., Inc.
12.1 Mechanism of Action Ponatinib is a kinase inhibitor. Ponatinib inhibited the in vitro tyrosine kinase activity of ABL and T315I mutant ABL with I...
Importance of five membered heterocyclic compounds in treatment of chronic myeloid leukemia by targeting various pathways.
Chronic myeloid leukemia (CML) is a clonal hematopoietic malignancy characterized by the presence of the Philadelphia chromosome, which generates the constitutively active BCR::ABL1 tyrosine kinase, d...
Roles of extracellular vesicles in the pathogenesis of chronic myeloid leukemia.
Extracellular vesicles (EVs) are lipid bilayer-enclosed particles released by cells into the extracellular space. They are produced by the majority of cell types under both physiological and pathologi...
Development of a blood test-based predictive scoring tool for treatment response in chronic myeloid leukemia.
The European LeukemiaNet recommendations for the management of chronic myeloid leukemia (CML) consider achievement of major molecular response (MMR) within 12 months to be an optimal response (OR...
An AI-Enabled Single-Cell Transcriptomic Analysis Pipeline for Gene Signature Discovery in Natural Killer Cells Linked to Remission Outcomes in Chronic Myeloid Leukemia.
A major technical challenge in single-cell transcriptomics is the absence of an integrative analytic pipeline that can simultaneously leverage gene regulatory network (GRN) architecture, AI-assisted g...
Evolution of the European LeukemiaNet recommendations for chronic myeloid leukemia.
Chronic myeloid leukemia (CML) management has been revolutionized by tyrosine kinase inhibitors (TKIs), leading to near-normal life expectancy for most patients diagnosed in the chronic phase. The Eur...
Targeting Mitochondrial Vulnerabilities in Chronic Myeloid Leukemia: From Pathobiology to Novel Therapeutic Opportunities.
Background : Mitochondria are multifunctional organelles that play a central role in maintaining cellular homeostasis by regulating energy metabolism, reactive oxygen species (ROS) generation, ion hom...
Hagop Kantarjian, MD, MD
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Franck-Emmanuel NICOLINI, MD
Centre Leon Berard
Brenda Sandmaier
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
📍 SEATTLE, WA
Minocher Battiwalla, MD, MD
National Institutes of Health- NHLBI
📍 NASHVILLE, TN
Brian J Druker
Providence Saint Joseph Medical Center/Disney Family Cancer Center
📍 Burbank, California
David Maloney
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium